There’s No Getting Around Resmed Inc. (NYSE: RMD) Success

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Yahoo Finance discussed the stock recently as it posted ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

RMD belongs to the Healthcare sector of the NYSE while operating in the Medical Instruments & Supplies industry. At the end of the last regular session, the stock closed at $190.11 and fluctuated between $192.44 as its day high and $190.09 as its day low. The current market capitalization of Resmed Inc. is $27.96B. A total of 0.82 million shares were traded on the day, compared to an average of 983.76K shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, RMD has seen 11 BUY and 20 SELL insider trades, representing the acquisition of 23,284 and the disposition of 25,632 shares. Over the last 12 months, there were 26 BUYs and 57 SELLs from insiders. Insiders purchased 100,607 shares during that period but sold 130,631.

In the most recent transaction, Sandercock Brett sold 3,000 shares of RMD for 152.62 per share on Nov 27. After the transaction, the Chief Financial Officer now owns 92,962 company shares. In a previous transaction on Nov 15, Farrell Michael J. sold 5,678 shares at 152.04 per share. RMD shares that Chief Executive Officer owns now total 440,986.

Among the insiders who sold shares, Rider Michael J disposed of 25 shares on Nov 01 at a per-share price of $143.42. This resulted in the Global General Counsel holding 7,358 shares of RMD after the transaction. In another insider transaction, Farrell Michael J. sold 5,675 shares at $140.70 per share on Oct 16. Company shares held by the Chief Executive Officer now total 449,360.

Dividend

Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Resmed Inc. pays an annual dividend of $1.95, resulting in a dividend yield of 1.02%, and it has a price to earnings (P/E) ratio of 31.49. RMD’s most recent ex-dividend date was 2/7/2024 when it declared a $0.48 quarterly dividend that was paid in cash on 3/14/2024. Previously, the company paid the dividend on 12/14/2023 with an ex-dividend date of 11/8/2023. The RMD stock dividend was $0.48 per share in cash.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for RMD in the last 3 months, the mean price target is $202.69 with high estimates of $237.03 and low estimates of $164.00. In terms of 52-week highs and lows, RMD has a high of $243.52 and a low of $132.24.

As of this writing, RMD has an earnings estimate of $TORM plc per share for the current quarter. EPS was calculated based on a consensus of Advanced Micro Devices, Inc. estimates, with a high estimate of $ResMed Inc. per share and a lower estimate of $CorMedix Inc.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. RMD’s latest balance sheet shows that the firm has $273.71M in Cash & Short Term Investments as of fiscal 2022. There were $917.55M in debt and $689.30M in liabilities at the time. Its Book Value Per Share was $30.47, while its Total Shareholder’s Equity was $3.36B.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RMD is Buy with a score of 4.23.

Most Popular

Related Posts